Eevia Health Partners with Canadian Nutraceutical Leader
Eevia Health has announced a strategic partnership with a leading Canadian nutraceutical company, marking a significant milestone in its global expansion strategy.
Sammanfattning
Eevia Health partners with a Canadian nutraceutical leader to boost global sales of its innovative FENO-SAMBUCUS™ 30 extract, enhancing its market reach and sustainability credentials.
Eevia Health, the innovative Finnish company known for its high-quality plant-based extracts, has taken a significant step forward in its global expansion strategy. The company recently announced a strategic partnership with a prominent Canadian nutraceutical player, a subsidiary of a multinational group. This collaboration aims to leverage the Canadian partner's extensive market reach and premium marketing capabilities to drive sales of Eevia's flagship product, FENO-SAMBUCUS™ 30, to new heights.
The relaunch of FENO-SAMBUCUS™ 30 earlier this year caught the attention of the Canadian company, thanks to its unique position in the market as a high-strength, excipient-free elderberry extract. With twice the amount of key bioactives compared to other products, FENO-SAMBUCUS™ 30 offers significant operational benefits for manufacturers, including reduced dosage volume and potential cost savings per dose.
Manufactured at Eevia's state-of-the-art green-chemistry facility in Finland, FENO-SAMBUCUS™ 30 is produced from European Elderberries and boasts a remarkable 30% anthocyanins and 50% total polyphenols. The product is not only potent but also sustainable, with a low carbon footprint and nearly sugar-free composition, setting a new benchmark for purity in the industry.
The partnership with the Canadian nutraceutical leader is a strategic move for Eevia Health, enabling the company to expand its footprint in the global market. The initial order of KEUR 70 signifies a promising start to this collaboration, which aligns with Eevia's mission to offer high-impact, science-backed health solutions worldwide.
From an investment perspective, this partnership positions Eevia Health as a strong contender in the nutraceutical sector, with potential for significant growth. The company's commitment to sustainability and innovation, combined with the marketing prowess of its new partner, suggests a promising future. Investors may want to consider this development as a positive indicator of Eevia's continued success and market expansion.
Källa
Sammanfattning
Eevia Health has formed a partnership with a global nutraceutical company based in Canada, which is part of a larger multinational group. This collaboration follows the relaunch of FENO-SAMBUCUS™ 30, a high-strength, excipient-free elderberry extract. The product is noted for its double potency compared to other market options, offering benefits like reduced dosage volume and cost efficiency. It is produced using sustainable methods at Eevia's Finnish facility and has a low carbon footprint. The partnership aims to leverage the Canadian company's strong sales and marketing capabilities to expand Eevia's global reach in the immune health sector. Eevia Health, founded in 2017 and listed on the Spotlight Stock Market in Sweden, specializes in bioactive compounds from plant materials, primarily sourced from Finnish and Swedish forests.
